💡 The tool, developed by Refeyn, uses light scattering to detect whether viral capsids used in gene therapy are filled with the DNA drug.
🔬 Unlike other methods, it can distinguish between empty and full capsids.
💰 At $175,000, it is smaller and cheaper than established instruments, making it accessible to smaller biotechs.
⚙️ The tool has also added Good Manufacturing Practice compliance and the ability to measure capsid titer.
Introduction:
Refeyn, a company that developed a benchtop tool for detecting empty-full viral capsids for gene therapy applications, has added new capabilities to work in commercial-scale manufacturing. This tool uses light scattering to determine if the protein shell of adeno-associated viruses (AAVs) used in gene therapy is full of DNA. The recent addition of Good Manufacturing Practice (GMP) compliance allows the tool to be used throughout the manufacturing process.
- Refeyn’s mass photometer uses light scattering to determine if the protein shell of adeno-associated viruses (AAVs) used in gene therapy is full of DNA.
- The new capabilities of the tool allow it to work in commercial-scale manufacturing, making it more accessible for smaller biotech companies.
- The tool is smaller and cheaper than established methods for measuring empty-full capsids, and it provides quicker results, allowing for optimization of the manufacturing process.
- Refeyn has also added the ability to measure the titer of capsids, allowing for a more accurate understanding of the contents of the test tube.
- The company has launched a system to work on larger viruses, such as adenoviruses and lentiviruses.
Conclusion:
Refeyn’s benchtop tool for detecting empty-full viral capsids for gene therapy applications has added new capabilities that make it suitable for commercial-scale manufacturing. This tool provides a faster and more accessible way to determine if the protein shell of adeno-associated viruses (AAVs) is full of DNA. With the recent addition of GMP compliance, it can be used throughout the manufacturing process. These advancements contribute to the optimization of gene therapy manufacturing and have the potential to benefit smaller biotech companies.
